Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Inclusion Criteria * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * age \> 18 * Karnofsky performance status \> 60% * Measurable disease on clinical exam or by RECIST criteria * One prior platinum-based systemic chemotherapy regimen for advanced disease is allowed but not required. Chemotherapy administered as a radiosensitizer in conjunction with primary radiotherapy is not considered a systemic chemotherapy regimen and is also allowed. Patients eligible for a higher priority study will be excluded. * Life expectancy \> 6 weeks * Peripheral neuropathy ≤ Grade 2 by CTC 3.0 criteria * Women of child-bearing potential must have a negative pregnancy test * Adequate hematopoietic function defined as: ANC ≥ 1500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 8 g/dL. * Adequate renal and hepatic function defined as: Bilirubin ≤ 1.5 times upper limit of normal (ULN); SGOT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 2.5 times ULN; Creatinine ≤ 2 times ULN. Exclusion Criteria * Patient has hypersensitivity to bortezomib, boron or mannitol. * Female subject is pregnant or breast-feeding. * Patient has received other investigational drugs with 14 days before enrollment * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Prior treatment with CAMPTOSAR or VELCADE * More than one prior treatment for metastatic disease. * Concurrent uncontrolled illness * Ongoing or active infection * History or active secondary cancer within the last 5 years, except for superficial basal cell skin cancers * Psychiatric illness or social situation that would preclude study compliance.